Adoptive T-cell transfer for cancer immunotherapy requires genetic modification of T cells with recombinant T-cell receptors (TCRs). Amphotropic retroviral vectors (RVs) used for TCR transduction for this purpose are considered safe in principle. Despite this, TCR-coding and packaging vectors could theoretically recombine to produce replication competent vectors (RCVs), and transduced T-cell preparations must be proven free of RCV. To eliminate the need for RCV testing, we transduced human T cells with ecotropic RVs so potential RCV would be non-infectious for human cells. We show that transfection of synthetic messenger RNA encoding murine cationic amino-acid transporter 1 (mCAT-1), the receptor for murine retroviruses, enables efficient transient ecotropic transduction of human T cells. mCAT-1-dependent transduction was more efficient than amphotropic transduction performed in parallel, and preferentially targeted naive T cells. Moreover, we demonstrate that ecotropic TCR transduction results in antigenspecific restimulation of primary human T cells. Thus, ecotropic RVs represent a versatile, safe and potent tool to prepare T cells for the adoptive transfer.
INTRODUCTION
Adoptive transfer of autologous T cells genetically modified to express tumor antigen reactive T-cell receptors (TCRs) results in tumor regression and has emerged as a powerful treatment option for patients with cancer. [1] [2] [3] [4] TCR gene transfer into primary human T cells to achieve this is most commonly carried out by transduction with amphotropic retroviral vectors (RVs). Amphotropic RVs bear safety risks as they infect human cells, and rare recombination events during RV production may contaminate therapeutic cell products with replication competent vectors. 5 Use of ecotropic RVs for this purpose would be safer, as human cells lack the mandatory receptor for murine retroviruses, the murine cationic amino-acid transporter 1 (mCAT-1). 6 For the same reason, ecotropic RVs cannot be used for transduction into human T cells. To enable their temporary competence for ecotropic transduction we transfected human T cells transiently with mCAT-1, thereby combining safety of ecotropic RVs with the efficiency of retroviral TCR transduction. This approach has proven successful for several nonlymphoid human cell types through the use of plasmids, adeno-associated viruses or lentiviruses as vectors for mCAT-1 transfer. [7] [8] [9] [10] Our objective was to adapt this concept to an ecotropic TCR transduction protocol so that it is technically feasible for clinical applications. In doing this, gain of safety has to be balanced against increased complexity of cell product preparation so overall efficiency is comparable to amphotropic TCR transduction. For this reason we resorted to synthetic messenger RNA (mRNA) transfer, which has various advantages over vector platforms used previously to deliver mCAT-1. Synthesis of mRNA based on in vitro transcription is far simpler than production of lentiviruses and adeno-associated viruses. Production and transfection of synthetic mRNA is classified as biosafety level 1, whereas amphotropic lentiviral transduction requires biosafety level 2. In contrast to plasmids, mRNA expression only requires cytoplasmic delivery, which is much more easily achieved than nuclear delivery of plasmids.
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Although the electroporation or even nucleofection of plasmids into T cells is inefficient and accompanied by high cell death rates (both around 50%), 12, 13 mRNA ensures superior gene transfer efficiency and high T-cell survival (both up to 85%).
14 Therefore, transient delivery of TCRs or chimeric antigen receptors with synthetic mRNA is considered an emerging tool for clinical adoptive transfer protocols. 15, 16 Our group's research has been dedicated to the improvement of the synthetic mRNA approach resulting in an optimized RNA vector platform, which via use of superior cap-analogs, optimized poly-A tails and stabilizing untranslated regions (UTRs) provides increased RNA stability as well as higher and more sustained protein expression. [17] [18] [19] In this paper we demonstrate that use of mRNA transfer technology allows rapid and efficient expression of mCAT-1 in human T lymphocytes, transiently sensitizing human T cells for ecotropic TCR transduction. This approach can be considered as an enabling technology to facilliate the further clinical development of adoptive T-cell immunotherapy.
RESULTS AND DISCUSSION
The overall objective of this study was to use mRNA-encoded mCAT-1 for sensitization of human T cells for ecotropic TCR transduction ( Figure 1) .
By formal comparison, mRNA has been shown to be superior to DNA for transfection of cell types other than T cells, such as K562 cells. 11 To assess whether this also holds true for T cells, we first compared mRNA and plasmid-based expression of the green fluorescent protein (GFP) in T cells after electroporation using identical parameters. We found that GFP expression was doubled in Jurkat76 (reaching >90%) and increased sevenfold in primary T cells (reaching around 70%) through the use of mRNA (Figure 2a) . We frequently achieved >80% transfection of primary T cells depending on the donor. Overall, we confirmed published RNA-transfer efficiencies, 14 as well as the superiority of RNA over DNA in transfections.
We then proceeded to assess whether mCAT-1 would also be translated to higher functional levels using mRNA, discernible by higher transduction rates with ecotropic RV. To this end we electroporated the same amount of mCAT-1-coding mRNA or plasmid DNA into human T cells and transduced these cells with a dsRed-encoding ecotropic vector. We spiked GFP (coded on mRNA or plasmid) into all samples and measured GFP expression as a surrogate marker for successful mCAT-1 transfer, as commercially available mCAT-1 antibody failed to distinguish transfected mCAT-1 from the human homolog in both flow cytometric and western blot analysis (data not shown). GFP spike-ins confirmed higher mRNA-based transgene expression (Supplementary Figure 1) . Accordingly mRNA-based mCAT-1 transfer resulted in doubled ecotropic transduction rates of Jurkat76 and markedly increased transduction of primary CD3+ T cells (Figure 2b ), whereas mock electroporated cells were not transduced. These data establish mRNA as the vector of choice to sensitize human T cells for ecotropic transductions.
Next, we sought to optimize mRNA concentration for maximal ecotropic transduction of Jurkat76 and primary CD3+ T cells. We found that transduction rates correlated with the mCAT-1 mRNA concentration reaching saturation at 10 ng μl − 1 mRNA in both cell types. Optimally, >90% of Jurkat76 ( Figure 2c ) and nearly 80% of primary human T cells ( Figure 2d ) were transduced, whereas mock electroporated cells as negative controls remained untransduced. The dependence of ecotropic transduction on transfected mCAT-1 RNA dose is in accordance with previous studies that correlated RV receptor transcript levels in mouse and human hematopoietic cells to transduction rates. 20, 21 To allow direct comparison with amphotropic transductions, CD3+ T cells were transduced with RV pseudotyped with vesicular stomatitis virus-G (VSV-G) protein and Gibbon Ape Leukemia virus (GALV) envelope. The amphotropic transduction rates between 30 and 40% that we achieved were within the reported range used for clinical applications (20-92%). 22, 23 However, ecotropic transduction was almost twice as efficient as amphotropic transduction, which indicates that mCAT-1 density maybe higher than GALV receptor density (Figure 2d ). Although our data show that a broad range of mCAT-1 RNA enables ecotropic transductions, we propose using at least 10 ng μl − 1 mCAT-1 mRNA as minimal dose to achieve robust results.
We repeatedly observed that mock electroporated cells were not transducible with ecotropic RVs. We therefore used ecotropic transducibility as a surrogate end point to estimate the duration of presence of functional mCAT-1 on the cell surface by transducing the T cells at different time points after mRNA electroporation. VSV-G-and GALV-pseudotyped RVs served as controls to monitor general transducibility during prolonged ex vivo culture of the T cells. Transduction rates were measured 72 h after each transduction, and GFP-encoding mRNA was spiked into the samples to monitor electroporation rates. In addition, we spiked the same amount of luciferase mRNA as mCAT-1 RNA into the samples and measured the decay of luciferase expression to estimate mCAT-1 half-life. We found that ecotropic transduction rates of mCAT-1-transfected T cells decreased rapidly after electroporation, reaching limit of detection within 72 h, and were negligible after 1 week. In contrast, transduction rates achieved with VSV-G-pseudotyped RV showed only slight variations (Figure 3a ). Luciferase expression decreased with similar kinetics as functional mCAT-1 expression approaching detection limits within a week (Figure 3b ). GFP mRNA expression was still readily detectable after 1 week, and proved high initial electroporation efficiencies (Figure 3c ). To further assess whether transgene expression following ecotropic transduction was similarly stable as that following pantropic transduction, we measured dsRED expression repeatedly within 10 days in cells transduced 24 h after electroporation. We found no differences in transgene stability ( Figure 3d ). As mCAT-1 expression decreased similarly to luciferase (half-life 3 h 24 ), we estimated half-life of mCAT-1 to be also about 3 h. Furthermore, stable transduction rates achieved with VSV-G-pseudotyped RV exclude that T cells generally lost transducibility during the prolonged duration of ex vivo culture. In summary, mCAT-1 expression is short-lived, which ensures that electroporated cells quickly lose their susceptibility toward ecotropic RV.
To investigate whether the expression of mCAT-1 RNA followed by TCR transduction has unintended effects on T cells, unstimulated CD3+ T cells were subjected to ecotropic transduction with a dsRed-encoding RV, followed by flow cytometric identification of naive T cells (CD45RA+ and CCR7+). Amphotropic RVs served as controls in these experiments. We found that the percentage of naive CD8+T cells was comparable in the transduced (dsRed positive) and non-transduced (dsRed negative) subpopulations, which indicated that mCAT-1 expression does not stimulate T cells (Figure 4a ). In contrast, amphotropic transduction (VSV-G-and ) and ecotropic transductions were performed the following day. (a) mCAT-1-electroporated activated T cells were transduced with an ecotropic retroviral vector coding for dsRed. To quantify cells with naive phenotype at day 2 after transduction, untransduced (dsRed negative) and transduced (dsRed positive) CD8+ cells were stained for CD45RA and CCR7. (b) Mock-electroporated T cells were transduced with VSV-G-or GALV-pseudotyped retroviral particles encoding GFP, mCAT-1-electroporated cells were transduced with ecotropic retroviral particles (mCAT+eco) encoding dsRed. Naive subsets of CD4+ and CD8+ cells were counterstained for CD45RA and CCR7 at day 2 post transduction with results obtained with cells from three different donors summarized in these graphs. **P o0.01, ***Po 0.001 student's t-test (c) Activated and electroporated CD8+ T cells were transduced with ecotropic retroviral particles encoding the alpha and beta-chain of a TCR specific for CMV pp65 epitope (NLVPMVATV) linked to GFP by 2A-self-cleavage sites. GALV-pseudotyped RVs) resulted in decreased numbers of naive T cells (Figure 4b) . We conclude that ecotropic RV targets naive T cells very efficiently and leads to improved preservation of naive phenotype in comparison with widely used amphotropic RV.
To test the functionality of T cells after ecotropic TCR transduction, we employed a system linking expression of a functional TCR to the expression of GFP by 2A-self-cleavage sites, ensuring retroviral co-delivery of TCR and GFP (Figure 4c ). The targeted antigen was the HLA-A*0201-restricted immunodominant epitope (NLVPMVATV) of Cytomegalovirus 65 kDa lower matrix phosphoprotein (CMV pp65). To study antigen-specific TCR signaling, cytotoxic CD8+ T cells were restimulated with CMV pp65 antigen-loaded K562-A2 cells 4 days after mCAT-1-mediated transductions. Only GFP-positive and thus TCR-expressing cells were stimulated antigen specifically as indentified by interferon γ production (Figure 4d ). Both, TCR-transduced and TCR-nontransduced populations did not release cytokines upon stimulation with an irrelevant HLA-A*0201-restricted control peptide, but were equally responsive to unspecific stimulation with Ionomycin and phorbol myristate acetate (exemplified in Figure 4d , summarized in Figure 4e ). These data indicate that transient mCAT-1 RNA transfer neither interferes with the functionality of the transduced TCR nor alters T-cell reactivity to antigen-specific and unspecific stimuli.
Altogether, our study provides evidence that mCAT-1 mRNAenabled ecotropic transduction of T cells is an effective method for the transduction of recombinant TCRs into human T cells. Recently, it has been reported that high titer ecotropic vector production can be easily optimized, upscaled and adapted to preclinical grade. 25 This, together with the protocol described here, may contribute in making ecotropic RV for clinical adoptive T-cell transfer a reachable goal. The use of mCAT-1-encoding mRNA described here ensures high efficiency with minimal increase in protocol complexity. Ecotropic transduction of human T cells confers a significant gain of safety and may obviate the need for replication competent vector testing of clinical grade vector batches.
MATERIALS AND METHODS

Cells and cell lines
All growth media and supplements were supplied by Life Technologies GmbH, Darmstadt, Germany, except when stated otherwise. Jurkat76 cells were grown in RPMI medium with 1% non-essential amino acids, 1% sodium pyruvate, 1% penicillin/streptomycin and 10% fetal calf serum (FCS) added. Platinum-E cells (Cell Biolabs, San Diego, CA, USA) were grown in Dulbecco's modified Eagle medium with 1% penicillin/streptomycin and 10% FCS. HEK293T cells were grown in Dulbecco's modified Eagle medium-F12, 1% penicillin/streptomycin and 10% FCS. To avoid medium supplementation with recombinant interleukin-3, Ba/F3 (DSMZ, Braunschweig, Germany) were transduced with p185(BCR/ABL) and adapted to factor-independent growth as described. 26 Ba/F3-p185 cells were grown in RPMI, 10% FCS and 1% penicillin/streptomycin. Cells were routinely tested for mycoplasma. Re-authentication of cells has not been performed since receipt.
T-cell isolation and stimulation
Human peripheral blood mononuclear cells of healthy donors were purified by Ficoll-Hypaque density gradient centrifugation. CD3+ or CD8+ T cells were isolated from peripheral blood mononuclear cells by a positive selection with anti-CD3 or anti-CD8 microbeads (Miltenyi Biotec; Bergisch Gladbach, Germany) according to the manufacturer's instructions. Cells were stimulated with plate-bound anti-CD3 (OKT3, 2 μg ml − 1 ) plus soluble anti-CD28 (2 μg ml − 1 ) together with interleukin-2 (50 U ml − 1 ) and transduced as stated elsewhere. On day 6 after activation, 5E5 CD8+ T cells were re-challenged with control antigen (2 μg ml − 1 , KASEKIFYV derived form SSX-2), CMV pp65 antigen (2 μg ml − 1 , NLVPMVATV) (Jerini, Berlin, Germany) or phorbol myristate acetate (10 ng ml − 1 , Sigma-Aldrich Chemie GmbH, Munich, Germany) plus Ionomycin (1 μg ml − 1 , SigmaAldrich Chemie GmbH) in the presence of 6E5 K562-A2 cells as antigen presenting cells (APCs) for 6 h. Brefeldin A (5 μg ml − 1 , Sigma-Aldrich Chemie GmbH) was added for 4 h.
Plasmids and cDNA
RVs deriving from PINCO, 27 have been converted to gateway destination vectors and have been previously described. 26 Genes of interest were first cloned into pENTR1A and shuttled into the RVs using the LR-clonase II enzyme mix according the manufacturer's instructions (Life Technologies GmbH). dsRed was inserted into the BamHI sites of pENTR1A. For in vitro transcription, genes of interest were cloned into pST1-2hBgUTR-A120, which features a 3′ human beta-globin UTR (hBgUTR) and a poly(A) tail of 120 nucleotides.
17 pST1 vectors coding eGFP or firefly luciferase have been previously described. 17, 18 The amino-acid sequence of mCAT-1 was retrieved from NCBI (NP_031539.3), the corresponding nucleotide sequence was codon optimized for the expression in human cells, equipped with a 5′ Kozak sequence, restriction sites for subcloning and assembled by gene synthesis (Geneart, Life Technologies GmbH). The coding region of mCAT-1 was inserted into the HindIII and BamHI sites of pST1-2hBgUTR-A120 and into the HindIII and XhoI sites of pCDNA3.1. For negative controls matching plasmid-based mCAT-1 transfer, eGFP was subcloned from pST1 into pCDNA3.1 via XhoI and HindIII. In initial experiments, pMAX-GFP (Lonza, Basel, Switzerland) was used (Figure 1a) . For the co-expression of TCR alpha and beta chains together with eGFP, a T2A followed by a P2A self-cleavage peptide was fused C-terminally inframe to the eGFP open-reading frame and inserted into pENTR1A. BamHI and SpeI sites between T2A and P2A, as well as ClaI and EcoRI sites 3′ of P2A allow in-frame assembly of the tripartite gene eGFP-T2A-TCR-beta-P2A-TCR alpha. The TCR chains used here are specific for CMV pp65. Plasmids coding murine leukemia virus (MLV)-gag-pol, VSV-G and GALV (pCDNA3-MLV-G/P; pMD2G and M620, respectively) were kindly provided from Manuel Grez (Georg Speyer Haus, Frankfurt, Germany).
Antibodies
Antibodies used for stimulation of primary T cells were anti-CD3 (Okt3, Janssen-Cilag GmbH, Neuss, Germany) and anti-CD28 (CD28.2, Biolegend, Aachen, Germany). Antibodies used for flow cytometry were anti-CD4-V450 (RPA-T4), anti-CD8-APC-Cy7 (SK1), anti-CD25-APC, anti-CCR7-PE-Cy7, INFγ-PE-Cy7 (4S.B3) (BD Bioscience, Heidelberg, Germany), anti-CD45Ra-PerCP-Cy5.5 (HI100) (eBioscience, Frankfurt, Germany), anti-TNFα-PE (cA2) (Miltenyi Biotec); CMV pp65 Dextramer-APC; A*0201; NLVPMVATV (Immudex, Copenhagen, Denmark). For determination of living cells either Aqua life/dead for 405 nm excitation (Life Technologies GmbH) or propidium iodide was used.
Production of viral supernatant and retroviral transduction
To generate ecotropic viral particles, Platinum-E cells were transfected with RVs using the Fugene-6 transfection reagent according to the manufacturer's instructions (Roche Applied Science, Mannheim, Germany). One day before transfection, Platinum-E cells were seeded in a density of 23 500 cells cm −2 and transfected with 0.28 μg DNA of the RV per cm 2 , medium was renewed 24 h after transfection. Retroviral supernatants were collected 48 and 72 h after transfection and titrated on Ba/F3-p185 cells. VSV-G-and GALV-pseudotyped viral particles were produced in HEK293T cells using Fugene-6 to co-transfect RVs and packaging constructs. Retroviral supernatants were collected 48 and 72 h after transfection and titers were evaluated using HEK293T cells. Preparations with titers above 0.5E6 I U ml − 1 were used for experiments. For transduction, retroviral supernatants were loaded onto Retronectin-coated non-tissue culture treated 24-well plates according to the manufacturer's instruction (Takara Bio Inc., Otsu, Japan), with the modification of 2-3 repeated cycles of virus loading and centrifugation (2500 r.p.m., 15°C, >15 min) of viral supernatant for increased binding. Thereafter, cells were seeded (4E4 adherent cells per well or 2E5 lymphocytes per well) and incubated at least 48 h with the viral particles.
RNA in vitro transcription and RNA electroporation
In vitro transcription and purification of RNA were previously described. 18, 28 Quality of purified RNA was assessed by spectrophotometry, and on-chip electrophoresis on the 2100 BioAnalyzer (Agilent, Santa Clara, CA, USA). RNA was electroporated into the different target cells using a square-wave electroporation device (BTX ECM 830, Harvard Apparatus, Holliston, MA, USA). The optimal pulse characteristics for each cell type Ecotropic T-cell transduction L Koste et al were carefully defined in preliminary experiments: Jurkat76 (688 V cm − 1 ; one pulse of 10 ms); primary lymphocytes (888 V cm − 1 ; one pulse of 10 ms). RNA concentrations used for each experiment are mentioned in the results section.
Flow cytometric analysis
For flow cytometric analysis, the cells were stained with Aqua life/dead according to the manufacturer's protocol, subsequently stained with the above mentioned antibodies in fluorescence-activated cell sorting buffer (phosphate-buffered saline; 10% FCS) and fixed with BD Stabilizing Fixative (BD Bioscience) before measurement. Flow cytometric data were acquired on a fluorescence-activated cell sorting Canto II flow cytometer (BD Bioscience) and analyzed by the corresponding Diva software or FlowJo software (Tree Star Inc., Ashland, OR, USA).
Luciferase assay
After electroporation 1E4 cells per well were plated in 96-well white microplates (Nunc, Langenselbold, Germany). Direct lysis of the cells and luciferase detection was performed with the Bright-Glo Luciferase Assay System (Promega, Madison, WI, USA) according to the manufacturer's instructions. Bioluminescence (photons per second (p s − 1 )) was measured using a microplate luminescence reader Infinite M200 (Tecan Group, Männedorf, Switzerland).
